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Abstract
Although association between persistent viral infection and allograft rejection is well characterized, few examples of T-cell
cross-reactivity between self-MHC/viral and allogeneic HLA molecules have been documented so far. We appraised in this
study the alloreactivity of CD8 T cell lines specific for immunodominant epitopes from human cytomegalovirus (HCMV) and
Epstein-Barr virus (EBV). CD8 T cell lines were generated after sorting with immunomagnetic beads coated with either
pp65495–503/A*0201, BMLF1259–267/A*0201, or BZLF154–64/B*3501 multimeric complexes. Alloreactivity of the CD8 T cell lines
against allogeneic class I MHC alleles was assessed by screening of (i) TNF-a production against COS-7 cells transfected with
as many as 39 individual HLA class I-encoding cDNA, and (ii) cytotoxicity activity toward a large panel of HLA-typed EBV-
transformed B lymphoblastoid cell lines. We identified several cross-reactive pp65/A*0201-specific T cell lines toward
allogeneic HLA-A*3001, A*3101, or A*3201. Moreover, we described here cross-recognition of HLA-Cw*0602 by BZLF1/
B*3501-specific T cells. It is noteworthy that these alloreactive CD8 T cell lines showed efficient recognition of endothelial
cells expressing the relevant HLA class I allele, with high level TNF-a production and cytotoxicity activity. Taken together,
our data support the notion that herpes virus-specific T cells recognizing allo-HLA alleles may promote solid organ rejection.
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Introduction
It is now well established that the memory subset of circulating
T cells contribute to alloresponse, thus explaining that viral
infections are associated with graft failure in human transplant
recipients [1,2,3]. A range of acute viral infections, most
particularly cytomegalovirus (HCMV) infection, has been linked
with initiating the clinical complications that often follow
transplantation [4]. The best evidence that HCMV is involved
in acute and chronic rejection is based on studies with the anti-
HCMV drug ganciclovir in humans and animal models that
demonstrate a reduction in allograft failure in solid organ
transplant patients [5]. HCMV could account for graft rejection
by selective endothelial cell activation thereby attracting and
activating alloreactive T cells [2]. Another factor of the association
between HCMV infection and allograft graft rejection could be
cross-reactivity of HCMV-specific T cells to allogeneic HLA
molecules. Persistent viral infections have a profound impact on T
cell repertoire, since they lead to long-term clonal expansions of
virus-specific memory CD8 T cells. Large clonal expansions of ab
T cells within the human peripheral repertoire have been
documented in several acute viral infections [6] and in healthy
individuals [7]. In particular, human CD8 memory T cell
repertoire is often dramatically skewed by predominant clones
directed against HCMV or Epstein-Barr virus (EBV), which can
persist unaltered for many years [8,9,10]. Through cross-
reactivity, these memory T cells could contribute to the
alloresponse, owing to their lack of requirement for co-stimulation,
easy and rapid activation, and vigorous effector functions [11].
Though association between persistent viral infection and
allograft rejection is well admitted, few examples of T-cell cross-
reactivity between self-MHC/viral and allogeneic HLA molecules
have been documented so far. The influence of antiviral T cell
responses on the CD8
+ T cell alloreactive repertoire was first
described for an EBV T cell response specific to the EBNA3A325–
333/B*0801 EBV epitope [12,13,14]. More recently, cross-
reactivity of HCMV-specific and herpes simplex virus-specific
CD8 T cells to allogeneic HLA alleles has been reported [15,16].
To appraise the contribution of EBV- or HCMV-specific CD8 T
cell responses to the allogeneic repertoire, we screened a number of
CD8 T cell lines, that had been sorted with recombinant peptide/
MHC class I (pMHC) multimeric complexes, on a large panel of
HLA class I alleles expressed either by transfected COS cells or by
EBV-transformed B lymphoblastoid cell lines (LCL) for cross-
reactivity to allogeneic class I HLA molecules. Our study was focused
on the pp65495–503/A*0201 HCMV epitope (NLVPMVATV)
[17] and two epitopes of early lytic EBV proteins (BZLF154–64/
B*3501: EPLPQGQLTAY [18,19] and BMLF1259–267/A*0201:
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12120GLCTLVAML [20,21]), forwhich immunodominance [17,19,22,23]
and high frequency [10,24] is well documented. This unveiled several
allospecific CD8 T cell responses, leading to cytotoxicity and TNF-a
production against primary endothelial cell cultures expressing the
relevant allogeneic HLA alleles. This might have important
physiopathological implications in an allograft setting, which are
discussed.
Results
Screening of HCMV- or EBV-specific CD8 T cell lines for
cross-recognition of allogeneic MHC molecules
To assess the influence of CD8 T cell responses specific to
HCMV or EBV to the allogeneic repertoire, we screened CD8 T
cell lines sorted with recombinant pMHC multimeric complexes
specific to HCMV (pp65495–503/A*0201) or EBV (BMLF1259–267/
A*0201 or BZLF154–64/B*3501) epitopes for cross-recognition of
allogeneic MHC class I molecules, taking into account the
immunodominance of those responses and the frequent expression
of A*0201 and B*3501 alleles (Table 1). Most T cell lines analyzed
were derived from PBL from healthy donors (D01 to D08, D12).
Other T cell lines were derived from PBL from patients suffering
from arthritis (D09 to D11, D13 to D16). The enrichment in EBV-
or HCMV-specific T cells was checked by staining by ad hoc
pMHC tetramers, and two successive sortings were made, when
necessary, to achieve a purity between 89 to 100% (Table 1,
Fig. 1.A, and data not shown). Staining of T cell lines before
sorting indicated frequencies comprised between 0.1 and 5.6%
(Fig. 1.B and data not shown). Two unsorted T cell lines, derived
from A2-negative donors were also included in the screening.
T cell lines were screened both for TNF-a production against
COS-7 cells transfected with as many as 39 individual HLA class
I-encoding cDNA, and for cytotoxicity toward a panel of 30 HLA-
typed LCLs (Table 2), in order to detect allo-MHC recognition.
Data are summarized in Table 1.
pp65495–503/A*0201 epitope specific T cells exhibit
alloreactivity against HLA-A*3001, A*3101, or A*3201
Cross-reactivity to allogeneic HLA molecules was found for 3
out of 11 pp65/A2-sorted T cell lines, each one recognizing a
different HLA-A allele. The T cell line derived from D03 killed
only the LCL SBN, the only one of the panel to express A*3201.
D01-derived T cell line killed LCL BOI and JHAF, sharing
A*3101 expression, and D08-derived T cell line killed LCL BAR,
the only one to express A*3001, but did not kill LCL DUC
A*3002
+ (Fig. 2A). The percentage of killing varied from 40 to
90%, probably reflecting the representation of the alloreactive T
cells within the polyclonal T cell line. In the COS transfection
assay, TNF-a production was observed only for the T cell line
derived from D03, that responded to COS cells expressing A*3201
(Fig. 2B). The cDNAs encoding HLA-A*3101 and -A*3001 were
not available, thus explaining that no response was observed for
the T cell lines derived from D01 and D08 in the COS assay.
Positive controls indicated that all pp65/A2-sorted T cell lines
killed LCL A*0201
+ loaded with the pp65495–503 peptide at 1 mM,
with 80% to 90% killing efficiency and produced high level TNF-a
against COS cells co-expressing HLA-A*0201 and pp65 (data not
shown). Two unsorted T cell lines, derived from HLA-A*0201-
negative donors were included in the screening. They showed
allorecognition of HLA-A*0201, producing TNF-a selectively
Table 1. Screening of CD8 T cell lines enriched in HCMV- or EBV-specific T cells for cross-reactivity to allogeneic MHC molecules.
Donor# Molecular HLA class I typing
% of tetramer-positive
T cells
Reactivity to
allogeneic HLAa
HLA-A* HLA-B* HLA-Cw*
pp65/A*0201-sorted T cell lines
D01 0201 0301 3501 4402 0401 0501 97 A*3101
D02 0201 33 08 14 07 08 98 none
D03 0201 0201 1302 5101 0202 0602 99 A*3201
D04 0201 ND ND ND 98 none
D05 0201 ND ND ND 99 none
D06 0201 ND ND ND 99 none
D07 0201 2301 2705 4402 0102 0509 98 none
D08 0201 2301 4101 4402 0501 1701 89 A*3001
D09 0201 30 08 44 04 07 98 none
D10 0201 0201 1501 4403 0304 0501 95 none
D11 0201 1101 0801 2705 01 07 97 none
BMLF1/A*0201-sorted T cell lines
D12 0201 3201 15 15 0303 04 93 none
D13 0201 0201 2705 4002 0102 1501 95 none
BZLF1/B*3501-sorted T cell lines
D14 0301 1101 0701 3501 04 07 92 none
D15 2402 3101 3501 4001 03 07 97 Cw*0602
D16 2402 3201 2705 3501 01 04 97 none
aCD8 T cell lines were screened on COS-7 cells transfected with individual HLA-encoding cDNA and TNF-a production was measured after a 6h-coculture. All T cell lines
were PBL-derived. ND : not determined.
doi:10.1371/journal.pone.0012120.t001
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+ LCL
(data not shown). This indicates that results obtained from the two
assays were fully consistent, thus validating the use of COS cells
transfected with individual HLA allele to screen for allorecognition
in the MHC class I context.
To appraise the polyclonality of the pp65/A2-specific T cell
lines, their TCR Vb repertoire was analyzed by immunofluores-
cence, using Vb-specific mAb (Table 3). T cell lines derived from
healthy donors used an heterogeneous set of TCR Vb families. In
contrast, T cell lines derived from RA patient PBL, that were
analyzed in a previous study [25], showed a dramatic skewing of
their TCR Vb repertoire, as .95% of T cells for a given donor
expressed the same Vb region. Three TCR Vb regions (TRBV10-
3, TRBV12-4 and TRBV20-1) were preferentially expressed by
most of the pp65/A2-specific T cell lines analyzed in the present
study.
To assess the percentage of alloreactive T cells within a given
pp65/A2-sorted T cell line and the TCR Vb region used by the
fraction of alloreactive T cells, we conducted a CD25 upregulation
assay. T cell lines were stimulated overnight with LCL expressing,
or not, the relevant allogeneic HLA allele and cells were triple
stained by anti-CD3-APC, anti-CD25-FITC and by anti-Vb-PE
mAb specific to each one of the TCR Vb used by this T cell line,
as indicated in Table 3. Such an analysis was done for the T cell
lines from D01 and D03. Data indicated that 40% of T cells within
the pp65/A2-specific T cell line from D01 responded to LCL
expressing A*3101 (Fig. 3A). Intracellular IFN-c detection was also
performed after stimulation of the D01-derived T cell line by
A*3101
+ LCL and 36% of cells were stained by anti-IFN-c mAb
(not shown), thus confirming the result of the CD25 assay. In
contrast, only 3% of T cells of the T cell line derived from D03
were stimulated by the LCL SBN, expressing A*3201. For the two
cell lines, a fraction of CD25
+ cells was stained by anti-Vb13.1
mAb (TRBV6-9; Fig. 3B), while a fraction of CD25
+ cells was not
stained by this mAb, nor by any of the other anti-Vb mAb (data
not shown). Due to the down-modulation of the TCR-CD3
complex following activation by Ag, most probably the whole
fraction of CD25
+ T cells activated by the allogeneic HLA
molecule is included in the TRBV6-9 subset. This suggests that
alloreactive T cells contained in the pp65/A2-specific T cell lines
from D01 and D03 used the same TCR Vb (TRBV6-9), though
they did not recognize the same allogeneic HLA allele.
Allorecognition of HLA-Cw*0602 by T cells specific to the
BZLF154–64/B*3501 epitope
Strong allorecognition of HLA-Cw*0602 was observed for the
BZLF1/B*3501-sorted T cell line from D15. This T cell line killed
selectively the four LCL of the panel (BAR, MHE, SBN, and
TIM), that shared Cw*0602 expression (Fig. 2A) and produced
TNF-a selectively against COS cells expressing Cw*0602 (Fig. 2B).
The CD25 assay, performed as described above, indicated that at
least 70% of T cells within this cell line acquired CD25 expression
upon stimulation with Cw*0602
+ LCL, but not with Cw*0602
2
LCL (Fig. 3C), thus indicating that T cells that recognize an EBV
epitope in the B*3501 context can cross-react with an HLA-C
allele. The two other BZLF154–64/B*3501-sorted T cell lines did
not respond to Cw*0602, though they were stained at .90% by
the BZLF154–64/B*3501 tetramer (Table 1). All three BZLF1/
B35-sorted T cell lines killed B*3501
+ LCL loaded with the
BZLF154–64 peptide (data not shown).
Analysis of TCR Vb repertoire of BZLF1/B*3501-sorted T cell
lines showed a limited set of TCR Vb regions, with a preferential
usage of Vb12 (TRBV10-3) for the three cell lines (Table 3).
Repertoire skewing in favor of Vb12 expression was the most
Figure 1. Enrichment in pp65495–503/A*0201- or BZLF154–64/B*3501-specific T cells after sorting of CD8 T cells with pMHC magnetic
multimers. (A) CD8 T cells, derived from the PBL from D01 and D03 were sorted with 245V mutated pp65495–503/A*0201 multimers, then expanded
in culture, and stained with PE-conjugated pp65495–503/A*0201 tetramers and FITC-conjugated anti-CD3. (B) CD8 T cells derived from the PBL from
D15 were sorted with 245V mutated BZLF154–64/B*3501 multimers, and then expanded in culture. Unsorted and sorted T cells were stained with PE-
conjugated BZLF1/B35 tetramers and FITC-conjugated anti-CD3. The percentage of positive cells is indicated in the upper right quadrant.
doi:10.1371/journal.pone.0012120.g001
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Vb region gene. The two other BZLF1/B35-sorted T cell lines
comprised about 50% of Vb12 T cells, though they did not exhibit
allorecognition of Cw*0602, thus indicating that alloreactive T
cells within D15-derived T cell line correspond to specific
clonotype(s) not found in the two other cell lines.
Alloreactive CD8 T cells killed efficiently endothelial cells
expressing the relevant class I HLA molecules
Endothelial cell cultures were tested for their capacity to activate
alloreactive CD8 T cell lines. As endothelial cell cultures,
expressing A*31, A*32 or Cw*0602 were available, we tested
their capacity to activate CD8 T cell lines that had shown
alloreactivity toward these HLA alleles: T cell line from D01,
alloreactive to A*3101, T cell line from D03, alloreactive to
A*3201 and T cell line from D15, alloreactive to Cw*0602. While
endothelial cell cultures alone did not produce TNF-a, they
induced TNF-a responses from T cell lines specific for the relevant
allogeneic MHC allele (Fig. 4A). Moreover, alloreactive CD8 T
cell lines killed the endothelial cells expressing the relevant
allogeneic MHC molecules, but not endothelial cells with
irrelevant allogeneic MHC alleles (Fig. 4B and Table 4).
Discussion
We identified in this study the cross-reactivity of herpesvirus-
specific CD8 T cell lines with allogeneic MHC class I molecules.
The rationale for analyzing these particular HCMV and EBV
epitopes was that their immunodominance has been well
documented [17,19,22]. CD8 T cell lines were screened on a
large panel of class I HLA alleles expressed either by LCL or by
COS-7 cells transfected with HLA-encoding cDNA. Identical
results were obtained in both assays, thus validating the use of
COS cells transfected with individual HLA allele to screen for
allorecognition in the MHC class I context. The interest to use T
cell lines sorted out with recombinant p/MHC multimeric
complexes was that they were 90 to 100%-enriched for T cells
of a given specificity, so that we could clearly link alloresponse to a
given viral epitope.
In agreement with a recent report by Amir et al. [26], our data
bring evidence that the pp65/A2 T cell response contributes to the
alloreactive repertoire. Cross-recognition of allogeneic HLA-A
molecules was found for three out of the eleven T cell lines tested
that showed cytolytic activity and cytokine production toward cells
expressing the relevant allogeneic HLA allele. This is in
accordance with previous data, obtained with EBV-specific CD8
T cells, which showed that allogeneic responses are considerably
stronger than syngeneic responses [12,13,14]. In contrast to the
strong cytotoxicity toward allogeneic LCLs exhibited by the T cell
lines we analysed, the pp65/A*0201-specific CD8 T cells cross-
reactive to allogeneic molecules described by Gamadia et al. were
not able to kill allogeneic LCLs, though they proliferated and
produced IFN-c against allogeneic LCL and killed autologous
LCL loaded with the pp65/A2 peptide [15]. We did not find any
recurrent cross-reactivity to allogeneic MHC alleles as each one of
these three alloreactive T cell lines recognized a different
allogeneic HLA-A allele: A*3001, A*3101, or A*3201. Remark-
ably, the pp65/A2-specific T cell line from D08 that showed
alloreactivity toward A*3001 did not respond to A*3002, though
these two allotypes differ from each other by only four amino acid
within a2 and a3 domains, indicating exquisite HLA specificity for
this allorecognition. Despite lack of recurrence, alloreactivity of
pp65/A2-specific T cells was focused against three HLA-A alleles,
that share .95% homology between each other and with HLA-
A*0201. This is in accordance with a retrospective survey of a
large cohort of hemopoietic stem cell donor/patient pairs with
single HLA mismatch, that had shown that allogeneic HLA class I
molecules with large sequence differences do not elicit a CTL
response [27]. In light of the A*3001, A*3101 and A*3201-cross-
recognition by pp65/A2-specific T cell lines, we tried to determine
retrospectively whether single HLA-A2-A30, A2-A31, and A2-A32
mismatch combinations could be associated with increased renal
graft loss [28] or higher incidence of severe GVHD [29]. However
no conclusive results could be drawn yet from such an analysis,
owing to the scarcity of such alleles, which are expressed by at
most 4% of the caucasian population.
We could have missed alloreactive clonotypes poorly represent-
ed within the polyclonal T cell line. However, our data indicate
that when as few as 3% of alloreactive T cells were present in the
polyclonal population, alloresponse was detected, thus document-
ing the exquisite sensitivity of the functional assays herein used. In
accordance with previous studies [17,24,25], most pp65/A*0201-
specific CD8 T cell lines screened for allorecognition showed a
Table 2. HLA class I typing of LCL.
LCL HLA-A* HLA-B* HLA-Cw*
ADA 0201 2705 4002 0102 1502
AK1 0201 0301 0702 1402 0702 0802
BAR 3001 2402 4403 5101 0602 1601
BAX 0101 0301 0702 1501 0303 0702
BOI 2402 3101 3501 4001 03 07
COL 0102 0801 3501 0401 07
CRE 0101 2301 0801 4403 0701 0401
D1 0201 0301 3501 4402 0401 0501
D 2 0 2 0 1 3 30 81 40 70 8
D45 0201 2902 0702 0801 0701 0702
DAB 0201 1101 1801 5501 03 07
DUC 3002 1801 0501
GAS 0301 2402 2705 5101 0202 1602
HOB 0101 0801 0701
HVI 0101 0201 0801 1501 0304 0701
JES 0201 2705 01
JHAF 3101 5101 08
KER 0101 6801 0801 5101 07 15
LEE 0301 15 27 ND
LEP 0201 2501 1801 4402 0501 1203
MHE 0201 33 14 57 0602 0801
NIJ 0201 33 08 58 0302 0304
PAU 0201 1801 4001 0304 1203
PIP 0102 0201 5701 4002 ND
SBN 0201 3201 1402 5701 0602 0802
SYL 0301 0801 1801 0701
TAY 0101 1101 0702 3501 0401 0702
TIE 0201 2402 2705 35 0202 0401
TIM 0201 2601 2703 4501 0102 0602
YOU 0102 2402 2702 3501 ND
ND : Not determined. LCL and the HLA triggering allorecognition are indicated
in bold.
doi:10.1371/journal.pone.0012120.t002
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clonotypes were screened concomitantly. Though alloreactive T
cells contained in the pp65/A2-specific T cell lines from D01 and
D03 used the same TCR Vb (Vb13.1), they did not recognize the
same allogeneic HLA allele. Moreover, despite pp65/A2-specific
T cell lines from D04 and D11 used preferentially the same TCR
Figure 2. Screening of HCMV- or EBV-specific CD8 T cell lines for cross-recognition of allogeneic MHC molecules. CD8 T cell lines,
sortedwith recombinant pMHC multimeric complexesspecificto HCMV (pp65495–503/A*0201)or EBVlytic epitopes (BMLF1259–267/A*0201 or BZLF154–64/
B*3501), were tested: (A) for cytotoxicity toward a panel of 30 HLA-typed LCL, in a 4-h chromium release assay (Effector-Target ratio 15:1). HLA-
specific killing of LCL was observed for 3 of the 11 pp65/A2-specific T cell lines tested: T cell line from D01 killed A*3101
+ LCL, T cell line from D03
killed A*3201
+ LCL, and T cell line from D08 killed A*3001
+ LCL. The BZLF1/B*3501-sorted T cell line from D15 killed LCL sharing Cw*0602 expression.
Only T cell lines that showed alloresponse are displayed. LCL triggering an alloresponse are shown as well as some of the tested LCL which do not
elicit a cytotoxic response. Cognate peptide-HLA complexes (pp65495–503/A*0201 or BZLF154–64/B*3501) were used as positive control. Data are
presented as the mean percentage lysis and are representative of 3 different experiments. (B) for TNF-a production toward COS-7 cells transfected
with plasmids encoding class I HLA alleles. T cells were added 2 days after the transfection, and the TNF-a content of the supernatant, expressed
in pg/mL, was estimated 6 h later by testing the toxicity of the supernatants for TNF-a sensitive WEHI-164 clone 13 cells. TNF-a production was
observed for the pp65/A*0201-sorted T cell line from D03, that recognized selectively COS cells expressing HLA-A*3201, and for the BZLF1/B*3501 T
cell line from D15 that recognized selectively COS cells expressing HLA-Cw*0602. Plasmids encoding class I HLA alleles that elicits a response are
shown as well as some of the plasmid encoding class I HLA alleles that do not induce TNF-a secretion. T cell lines that did not produce TNF-a are not
represented. Cognate peptide-HLA complexes (pp65495–503/A*0201 or BZLF154–64/B*3501) were used as positive control. One out three
independent experiments is shown.
doi:10.1371/journal.pone.0012120.g002
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Collectively, these results suggest that alloreactivity exhibited by
some of the pp65/A2-specific T cell lines analyzed in this study
was linked to particular clonotypes.
Though several HLA-C locus mismatch combinations have
been described to be significant risk factors for severe acute graft-
versus-host disease GVHD [29], allorecognition of HLA-Cw
alleles has been poorly documented until now [29,30]. This study
shows allorecognition of HLA-Cw*0602 by a BZLF154–64/
B*3501-sorted T cell line, and this is, to our knowledge, the first
example of cross-recognition of an HLA-Cw allele by HLA-B-
restricted T cells. Cross-reactivity to Cw*0602 was observed in
only one BZLF1/B*3501-specific T cell line out of three, thus
indicating that alloreactivity is mediated by private T cell
clonotype(s). It has been reported that a recurrent CDR3 sequence
using TRBV10-3 is found in CTL recognizing BZLF154–64/
B*3501 [23]. Thus, the bulge of the EPLP 11-mer has been
postulated to constrain TCR diversity. As a similar predominant
useofTRBV10-3hasbeenobservedinthe 3 analyzed BZLF154–64/
B*3501-sorted T cell lines but only one exhibit a cross-reactivity to
Cw*0602, it would be of interest to characterize the CDR3
sequences in order to determine if a minor difference in TCR
sequence influence the allo-cross-reactivity with HLA-Cw*0602.
Again, this underlies the difficulty to predict alloreactivity, given
the huge number of HLA alleles and diversity of clonotypes
directed against a particular p/MHC complex. Analysis of
alloreactive T cell populations infiltrating human allografts
undergoing rejection have shown highly biased TCR usage,
associated in some cases with predominance of a single clone [31].
Alloreactive T cell clonal expansions have also been identified in
vivo during acute GVHD and persistence of these T cells for up to
one year has been reported [32]. Although the basis for this limited
diversity is unclear, it is possible that pre-existing expansions of
primed alloreactive T cells could play a role in graft rejection or
GVHD.
A range of acute viral infections have been linked with initiation
of complications that often follow transplantation, and most
attention has focused on the role of herpesvirus infections
[1,2,3,33]. In this context, the influence of the public CD8 T
cell response to the EBNA3A325–333/B*0801 EBV epitope on
the allogeneic repertoire has been well documented [12,13,14].
Clones were isolated, that displayed dual specificity for the
EBNA3A325–333/B8 epitope and for HLA-B*14, B*44 or B*35
alleles, as alloantigens [12,13]. Each distinct pattern was found to
be associated with a public TCR. The public TCR associated with
B44 allorecognition was shown to be alloreactive against B*4402
and B*4405, but not B*4403 [12,33]. These three allotypes differ
from each other by only 1 or 2 amino acids; yet this difference is
enough to invoke a substantial difference in T cell recognition.
These reports were the first to demonstrate that a history of EBV
infection can augment responsiveness to particular alloantigens.
Interestingly, HLA-B44 was identified as a ‘taboo mismatch’ for
HLA-B8
+ renal transplant recipients [34].
While it has long been established that human vascular
endothelium can activate alloreactive CD8 T cell in vitro [35]
very few studies have examined in detail the response of
alloreactive CD8 T cells toward endothelial cells. Here we show
that alloreactive CD8 T cell lines efficiently killed endothelial cells
expressing the relevant allogeneic HLA allele, and produced high
level TNF-a in response to these allogeneic endothelial cells. These
data clearly indicate that endothelial cells cultivated in vitro are
targets for alloreactive CD8
+ T cells. Allograft rejection often
involves injury of graft endothelium lining both large and small
vessels. Human vascular endothelial cells display both class I and
class II MHC molecules and are directly recognized in vitro by
CD8
+ and CD4
+ alloreactive T cells, respectively [35,36,37].
Table 3. Analysis of the TCR Vb repertoire of pp65495–502/A*0201- or BZLF1/B*3501-sorted T cell lines, using TCR Vb-specific mAb.
TCR Vb specific mAb
TRBV
2
(22)
3-1
(9)
4-1
(7.1)
4-3
(7.2)
5-1
(5.1)
5-5
(5.3)
5-6
(5.2)
6-2
(13.2)
6-6
(13.6)
6-9
(13.1)
9
(1)
10-3
(12)
11-2
(21.3)
12-4
(8)
13
(23)
14
(16)
18
(18)
19
(17)
20-1
(2)
25-1
(11)
27
(14)
28
(3)
29-1
(4)
30
(20)
pp65/A*0201-sorted T cell lines
D01 18.2 57.4 10.6 12.3
D02 1.6 8.2 89.2
D03 1 1.1 2 2.2 20.8 2.2 1.3 6.9 10.3 1.1 1.2 13.2 2.7
D04 91.5 6.1
D05 6.9 1.1 2 20.9 5.3 2.4 1 6.8 24.7 2.3
D06 9.5 3.4 2.3 41.4 1.3 1.4 11.7 27.7
D07 28.4 21.1 3.9 8.7 12.1 1.6 2.5 10.2
D08 1.8 1.7 2.6 42.3 1 8.5
D09 100
a
D10 99.0
D11 100
a
BZLF1/B*3501-sorted T cell lines
D14 1.1 2.9 48.8 2.3 36.6 5.2
D15 1.2 96.4
D16 3.9 55.2 26.3 16.4
The percentage of pp65/A*0201- or BZLF1/B*3501-specific T cells stained by the various anti-TCR Vb mAb is mentioned according to the IMGT nomenclature (Beckman
Coulter anti-TCR Vb name is indicated in bracket). All T cell lines were derived from PBL, either from healthy donors or from RA patients.
aPercentage determined by TCR sequencing (ref. 28). T cell lines exhibiting alloreactivity are marked in bold.
doi:10.1371/journal.pone.0012120.t003
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revealed that human endothelial cells are capable of triggering
graft rejection by adoptively transferred alloreactive T cells [38].
This issue is important in transplantation because, unlike
hemopoietic APCs, allogeneic vascular endothelium remains in
the allograft indefinitely.
Materials and Methods
Ethics Statement
PBL from healthy donors were obtained from the blood bank
(EFS Pays de la loire), which informed the healthy donors about
the final use of their blood. Based on their choice regarding the
destination of their blood (research vs. medical purpose), healthy
donors signed a consent statement. The approval of an ethical
committee was thus not necessary. A signed convention was
established between our institution (INSERM) and the blood bank
(EFS Pays de la Loire) to have access to PBL from healthy donors
for research purpose.
T cell lines and culture
T cell lines were derived from PBL, originating either from
healthy donors (D01 to D08, and D12) or from patients suffering
from arthritis (D09 to D11, and D13 to D16) that were recruited
by the department of Rheumatology (Centre Hospitalier de
l’Universite ´ de Nantes, Nantes, France), as previously described
[20]. PBMC were separated by Ficoll density centrifugation (LMS
Eurobio). HLA class I genotyping of donors (Table 1) was
performed by the Etablissement Franc ¸ais du Sang (Nantes,
France).
T cells were maintained in RPMI 1640 medium supplemented
with 10% FCS, 1mM L-glutamine and 150 U/mL recombinant
IL-2 (hereafter referred to as IL-2/CM). CD8
+ T lymphocytes
were positively selected by magnetic cell sorting from PBL using
anti-CD8 mAb, then expanded in vitro under nonspecific
stimulation in IL-2/CM supplemented with leukoagglutinin at
1 mg/mL, irradiated allogeneic PBL and LCL as described [39].
T cells were maintained for at least 3 weeks without restimulation.
Target cells
A panel of thirty LCL was used. They were generated by
exogenous transformation of peripheral B cells with EBV-
containing supernatant from the virus-producing B95.8 marmoset
cell line and were cultured in RPMI medium supplemented with
10% fetal calf serum (FCS). Human arterial endothelial cells
(HAEC) were isolated from renal artery patches collected at the
time of kidney transplantation, harvested according to good
Figure 4. Allorecognition of human endothelial cell cultures by
CD8 T cell lines enriched in herpesvirus-specific T cells. T cell
lines from D01 and D03, sorted with pp65495–503/A*0201 multimers,
were tested against HAEC #4373, #3315, and #3376, while T cell line
from D15, sorted with BZLF154–64/B*3501 multimers, was tested against
HAEC #3643 (Cw*0602+) and #1415 (Cw*0602-) for TNF-a production
(A) and cytotoxicity (Effector-Target ratio 15:1) (B). TNF-a production
was measured as indicated in Figure 2 legend. Only the endothelial cell
lines expressing the relevant allogeneic HLA allele induced cytotoxicity
and TNF production by the CD8 T cell lines tested. The data are
representative of 3 different experiments.
doi:10.1371/journal.pone.0012120.g004
Table 4. HLA class I typing of endothelial cells.
Endothelial cells HLA-A* HLA-B* HLA-Cw*
HAEC 1415 01 02 07 08 0702
HAEC 3315 30 31 37 39 ND
HAEC 3376 24 31 35 60 ND
HAEC 3643 01 02 15 57 0602
HAEC 4373 02 32 44 55 ND
ND : Not determined.
doi:10.1371/journal.pone.0012120.t004
Figure 3. Estimation of the percentage of alloreactive T cells within T cell lines sorted with pMHC multimers. T cell lines from D01,
alloreactive to A*3101 (A), from D03, alloreactive to A*3201 (B), and from D15, alloreactive to Cw*0602 (C) were stimulated with allogeneic LCL cells
expressing, or not, the relevant allogeneic HLA allele (E:T=1:1). Sixteen hours later, cells were double stained by anti-CD25-FITC and anti-CD3-APC
mAb. LCL expressing the relevant allogeneic HLA molecules induced CD25 expression by alloreactive T cells. The % of CD3
+ T cells stained for CD25 is
indicated. T cell lines from D01 and D03 were triple stained by anti-CD3-APC (for gating T cells), anti-CD25-FITC and anti-Vb-PE mAb and analysed by
flow cytometry using a BD FACSCalibur (Becton Dickinson, san Jose, CA). Data are shown for anti-Vb13.1 (TRBV6-9), only, as cells double stained by
anti-CD25 and other anti-Vb were not found. The % of CD3
+ T cells stained for CD25 or for the TCR Vb13.1 (TRBV6-9) region is indicated. Data are
representative of 3 different experiments.
doi:10.1371/journal.pone.0012120.g003
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Health Minister Project nu02G55), and cultured as described
previously [40]. All target cells were typed by HLA class I DNA
sequencing (Table 2 and 4).
Immunomagnetic cell sorting
The following antigenic peptides were used: pp65495–503/
A*0201 from the HCMV pp65 protein; BZLF154–64/B*3501,
BMLF1259–267/A*0201, from lytic EBV proteins (Genosys).
Soluble pMHC monomers were synthesized as previously
described [41,42]. They comprised mutated HLA I heavy chains,
with an Ala to Val substitution in the a3 domain at position 245,
decreasing the affinity for the CD8 co-receptor. Sorting of antigen-
specific T cells using recombinant pMHC complexes loaded onto
streptavidin-coated magnetic microbeads was performed on CD8-
sorted T lymphocytes, as described [41,42]. T cells were then
expanded in vitro under non-specific stimulation, as described
above, and maintained for 3 weeks without restimulation before
analysis. The purity of Ag-specific T cells after one sorting was
checked by tetramer staining. No major perturbation in the TCR
Vb repertoire is induced by the culture system [43].
Flow cytometric analysis
T cell lines were phenotyped for 24 TCR Vb expression
(IOTest Beta Mark PN IM3497) and anti-CD3-PE-Cy5 mAb
(Beckman Coulter). Staining with pp65495–503/A*0201, BZLF154–
64/B*3501 or BMLF1259–267/A*0201 tetramers was performed at
4uC with PE-labeled pMHC complexes at 10 mg/mL and anti-
CD3-FITC mAb (Beckman Coulter) for 30 minutes at 4uC, as
described previously [41,42]. Double stained cells were analyzed
by flow cytometry (BD FACSCalibur; Becton Dickinson). Data
analysis was performed using CellQuest Pro software (Becton
Dickinson).
Plasmids
Plasmids encoding the following HLA antigens were included in
the analysis: A*0101, A*0201, A*0301, A*1101, A*2402, A*3201,
A*3402, A*6801, B*0702, B*0801, B*1302, B*1401, B*1516,
B*1801, B*2701, B*2702, B*2704, B*2705, B*2706, B*2709,
B*3501, B*3508, B*4001, B*4002, B*4402, B*4403, Cw*0102,
Cw*02021, Cw*0302, Cw*0303, Cw*0401, Cw*0501, Cw*0602,
Cw*0701, Cw*0702, Cw*0802, Cw*1402, Cw*1501, Cw*1601.
Plasmids encoding BMLF1, BZLF1, and pp65 were also used.
Transient transfection of COS-7 cells and TNF-a assay
Transfection of COS-7 cells was performed by the DEAE-
dextran-chloroquine method, as described [20]. COS-7 cells were
either transfected with 100 ng of cDNA encoding one of the 39
HLA class I-encoding cDNAs, that were available, or cotrans-
fected with 100 ng of an expression vector encoding EBV or CMV
protein and 100 ng of an expression vector encoding the
restricting HLA allele. Transfected COS-7 cells were tested 48 h
after transfection for their ability to stimulate the production of
TNF-a by CD8 T cell lines. Briefly, 5610
3 cells from a CD8 T cell
line were added to transfected COS-7 cells, culture supernatants
were harvested 6 h later and their TNF-a content was determined
by measuring their cytotoxicity on WEHI-164 clone 13 cells in a
MTT colorimetric assay [44,45]}.
Lymphocyte functional assays
Cytotoxicity of T cell lines against LCL or primary cultures of
endothelial cells was evaluated in a standard 4h
51Cr-release assay,
as previously described [46]. When used, synthetic peptides were
directly added to
51Cr-labeled targets and incubated for 1 hour
before excess unbound peptide was washed off. Results are
expressed as percent specific
51Cr lysis=(experimental release -
spontaneous release)/(maximum release - spontaneous release)6
100%. Maximum and spontaneous release were determined by
respectively adding 1% Triton X-100 or medium to target cells in
the absence of effector cells. Each test was performed in triplicate
at the indicated E:T ratio.
In TNF-a release assays, 5610
3 T cells were incubated with
cultured HAEC (3610
4 cells/well) generated from different
donors and the amount of TNF-a released in the supernatant
was estimated after 6 hours by the WEHI-164 cytoxicity assay
[44].
To assess the percentage of alloreactive T cells within a given T
cell line, T cells (1.5610
5 cells/well) were stimulated overnight
with allogeneic LCL cells expressing or not the relevant allogeneic
HLA allele (E:T=1:1). Sixteen hours later, cells were double
stained by anti-CD25-FITC (BD Pharmingen) and anti-CD3-APC
mAb (Beckman Coulter), and analyzed by flow cytometry using a
BD FACSCalibur (Becton Dickinson, san Jose, CA). To determine
the TCR Vb region used by the fraction of alloreactive T cells, the
same protocol of stimulation with allogeneic LCL was followed
and cells were triple stained by anti-CD3-APC, anti-CD25-FITC
and by anti-Vb-PE mAb specific to each one of the TCR Vb used
by those T cell lines, (Beckman Coulter).
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